[{"id":"01c28c82-a9b1-4732-b168-15b5fcf2427e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01138384","created_at":"2021-01-18T04:31:34.030Z","updated_at":"2025-02-25T13:15:56.714Z","phase":"Phase 1/2","brief_title":"Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT01138384","lead_sponsor":"NCIC Clinical Trials Group","biomarkers":" HER-2","pipe":" | ","alterations":" EGFR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib • foretinib (GSK1363089)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 10/27/2010","start_date":" 10/27/2010","primary_txt":" Primary completion: 05/14/2014","primary_completion_date":" 05/14/2014","study_txt":" Completion: 02/13/2015","study_completion_date":" 02/13/2015","last_update_posted":"2023-08-04"},{"id":"0b05481d-c3c1-4ad2-939c-6638e0bf26e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01068587","created_at":"2021-01-18T04:12:43.648Z","updated_at":"2025-02-25T13:15:36.669Z","phase":"Phase 1/2","brief_title":"MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy","source_id_and_acronym":"NCT01068587","lead_sponsor":"NCIC Clinical Trials Group","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression • EGFR negative","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • erlotinib • foretinib (GSK1363089)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 01/21/2010","start_date":" 01/21/2010","primary_txt":" Primary completion: 03/21/2014","primary_completion_date":" 03/21/2014","study_txt":" Completion: 02/13/2015","study_completion_date":" 02/13/2015","last_update_posted":"2023-08-04"},{"id":"b94b3525-620b-43a3-9845-f9baaaf451fd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01147484","created_at":"2021-01-18T04:34:00.932Z","updated_at":"2025-02-25T13:15:58.693Z","phase":"Phase 2","brief_title":"A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer","source_id_and_acronym":"NCT01147484","lead_sponsor":"NCIC Clinical Trials Group","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e foretinib (GSK1363089)"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 09/02/2010","start_date":" 09/02/2010","primary_txt":" Primary completion: 12/14/2014","primary_completion_date":" 12/14/2014","study_txt":" Completion: 02/13/2015","study_completion_date":" 02/13/2015","last_update_posted":"2023-08-04"},{"id":"b4463d15-de56-4fd6-972b-59c93012b2a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT00725712","created_at":"2021-01-18T02:43:55.764Z","updated_at":"2024-07-02T16:37:18.495Z","phase":"Phase 2","brief_title":"Study of GSK1363089 in Metastatic Gastric Cancer","source_id_and_acronym":"NCT00725712","lead_sponsor":"GlaxoSmithKline","biomarkers":" KDR • VEGFA","pipe":"","alterations":" ","tags":["KDR • VEGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e foretinib (GSK1363089)"],"overall_status":"Completed","enrollment":" Enrollment 74","initiation":"Initiation: 03/31/2007","start_date":" 03/31/2007","primary_txt":" Primary completion: 11/01/2009","primary_completion_date":" 11/01/2009","study_txt":" Completion: 11/30/2009","study_completion_date":" 11/30/2009","last_update_posted":"2017-08-24"}]